Navigating an Increasingly Complex Framework to Improve Patient Outcomes With ICI-Based Therapy

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

Events

Date / Time
Event Details

Faculty

Goal Statement
The goal of this activity is to improve the confidence and competence of oncologists, emergency medicine physicians, pulmonologists, gastroenterologists, nurse practitioners, clinical pharmacists, nurses, and other healthcare professionals caring for patients with cancer treated with immune checkpoint inhibitors.

Target Audience
This program is intended for oncologists, emergency medicine physicians, pulmonologists, gastroenterologists, nurse practitioners, clinical pharmacists, nurses, and other healthcare professionals who manage patients receiving immune checkpoint inhibitors.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the key principles of tumor immunology and immunotherapy
  • Review the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology
  • Summarize the current understanding of investigational immuno-oncology pathways that may be targeted to potentially overcome immune evasion and resistance
  • Compare the safety profile and tolerability of immune checkpoint inhibitors to chemotherapy
  • Understand the unique spectrum of potential immune-related adverse events of individual immune checkpoint inhibitors including incidence, onset, and severity
  • Manage specific types and grades of immune-related adverse events in patients receiving immune checkpoint inhibitors
  • Evaluate the clinical utility of predictive biomarkers for immune checkpoint inhibitor response and resistance
  • Summarize ongoing research regarding the utility of biomarkers, PD-L1, microsatellite instability/mismatch repair, tumor mutational burden, DNA damage repair, T-cell functional state, composite biomarkers, or other host factors predictive of response to and/or toxicities associated with immune checkpoint inhibitors

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. UAN: JA4008176-0000-20-135-L01-P

Type of Activity: Knowledge

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.